Skip to content

Evaluation of bioequivalency of Gemfibrozil Capsule

Comparative bioequivalence study of the Gemfibrozil 300mg capsule manufactured by Poursina Pharma Company vs Lopid® capsule manufactured by Pfizer Pharmaceutical Company in healthy volunteers.

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT20231108059993N2
Enrollment
24
Registered
2025-03-30
Start date
2025-04-09
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bioequivalence study in healthy volunteers.

Interventions

Sponsors

Poursina Pharmaceutical Company
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Volunteers should be healthy and non smoking The weight range of participating candidates should be between 60-100 kg Candidates should be healthy in terms of physical examination, ECG and the following laboratory tests: Hemoglobin, Hematocrit, Red and White Blood Count, MCV (Mean Body Volume), MCH (Mean Body Hemoglobin), Routine Urinalysis, Total Cholesterol, Triglyceride, Total Proteins, albumin, uric acid, total bilirubin, alkaline phosphatase, gamma glutamyl transpeptidase (?-GT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), urea, creatinine and fasting blood glucose.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Plasma concentration of the drug. Timepoint: 14 sampling time included pre-dose (time 0) and at the following hours post-dose: 0/5, 1, 1/5, 2, 2/5, 3, 4, 5, 6, 7, 8, 10, and 12 h. Method of measurement: Liquid Chromatography with tandem mass spectrometry (LC-MS-MS).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaeed Ghanbarzadeh

Darou Shimi Teb Sanjesh Company

s_ghanbarzadeh@yahoo.com+98 41 3383 2649

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026